Abstract： Uterine malignant tumors mainly include cervical cancer and endometrial cancer, which are the second and third most common female malignant tumors in China, respectively. The mortality of uterine malignant tumors is increasing by years, and the patients tend to be younger. In order to achieve individualized and accurate treatment, accurate staging of uterine lesions and high-quality therapeutic evaluation are needed. PET imaging of uterine malignant tumors, including glucose metabolism, cell proliferation, estrogen receptor, somatostatin receptor, hypoxia imaging and FAPIs imaging, has significant advantages in tumor staging, monitoring response to targeted therapy, and early identification of chemoradiotherapy resistance.